<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002566</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000063579</org_study_id>
    <secondary_id>FRE-IT94</secondary_id>
    <secondary_id>FRE-FNCLCC-IT94</secondary_id>
    <secondary_id>NCI-F94-0019</secondary_id>
    <nct_id>NCT00002566</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors</brief_title>
  <official_title>INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not known whether combining chemotherapy with bone marrow&#xD;
      transplantation is a more effective treatment for men with germ cell tumors.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy&#xD;
      with bone marrow transplantation in treating men with relapsed germ cell tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the event-free survival of male patients with germ cell tumors in&#xD;
      relapse or first partial remission treated with salvage therapy comprising cisplatin,&#xD;
      etoposide, and ifosfamide (PEI) or vinblastine, ifosfamide, and cisplatin (VeIP) with or&#xD;
      without high-dose carboplatin, etoposide, and cyclophosphamide, followed by autologous bone&#xD;
      marrow and/or peripheral blood stem cell transplantation.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior&#xD;
      complete remission to first-line treatment (yes vs no), primary site of disease (testicular&#xD;
      vs retroperitoneal vs mediastinal), and lung metastases at study entry (yes vs no).&#xD;
      Autologous bone marrow and peripheral blood stem cells (PBSC) are harvested. Part I&#xD;
      (salvage): Patients are assigned to regimen A if they previously received vinblastine as part&#xD;
      of a first-line treatment, such as cisplatin, vinblastine, and bleomycin (PVB) or cisplatin,&#xD;
      cyclophosphamide, doxorubicin, vinblastine, and bleomycin (CISCA VB). Patients are assigned&#xD;
      to regimen B if they previously received etoposide (VP-16) as part of a first-line treatment,&#xD;
      such as bleomycin, VP-16, and cisplatin (BEP). Regimen A: Patients receive cisplatin IV over&#xD;
      2 hours, VP-16 IV over 2 hours, and ifosfamide IV over 1 hour on days 1-5 (PEI). Regimen B:&#xD;
      Patients receive cisplatin and etoposide as in regimen A and vinblastine IV on days 1 and 2&#xD;
      (VeIP). Treatment on both regimens continues every 3 weeks for 2 courses. Patients with&#xD;
      refractory disease at day 43 are taken off study. Part II: Patients are randomized to 1 of 2&#xD;
      treatment arms. Arm I: Patients receive 2 additional courses of PEI or VeIP. Arm II: Patients&#xD;
      receive 1 additional course of PEI or VeIP, followed by 1 course of high-dose carboplatin IV&#xD;
      over 2 hours, VP-16 IV over 2 hours, and cyclophosphamide IV over 1 hour on days 1-4.&#xD;
      Autologous bone marrow and/or PBSC are reinfused on day 7 of the fourth course for patients&#xD;
      on both arms. Patients on both arms with residual disease after the fourth course may undergo&#xD;
      surgery.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 280 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1994</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of testicular or extragonadal male germ cell tumors Must&#xD;
        meet 1 of the following conditions after completion of platinum-based first-line&#xD;
        chemotherapy: Complete remission (CR) followed by relapse Partial remission (PR) Prior&#xD;
        resection of viable malignancy with elevated tumor markers allowed Initial bulky disease&#xD;
        with no CR (significantly reduced but still abnormal in plateau) allowed if there is an&#xD;
        increase in biological tumor markers or development of new metastases Seminoma with relapse&#xD;
        after CR or PR to cisplatin-based chemotherapy allowed No pure seminoma pre-treated with&#xD;
        carboplatin No refractory disease (i.e., documented increase in tumor burden and/or serum&#xD;
        tumor marker level during or within 1 month after platinum-containing chemotherapy) CNS&#xD;
        involvement allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Sex: Male Performance status: WHO 0-2 OR&#xD;
        Karnofsky 50-100% Life expectancy: No limits on life expectancy due to severe non-malignant&#xD;
        disease Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified&#xD;
        Cardiovascular: No severe cardiac disease that would interfere with study therapy&#xD;
        Pulmonary: No severe pulmonary disease that would interfere with study therapy Other: HIV&#xD;
        negative No severe neurologic or metabolic disease that would interfere with study therapy&#xD;
        No psychological, socioeconomic, or geographic circumstances that would preclude study No&#xD;
        other concurrent malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy for&#xD;
        metastatic disease allowed Surgery: See Disease Characteristics Prior surgery for&#xD;
        metastatic disease allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose-Louis Pico, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2004</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>extragonadal germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

